drug

omecamtiv mecarbil

1 story · latest Nov 4, 2026

Follow omecamtiv mecarbil. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Cytokinetics

Timeline

Cytokinetics posts Q3 2026 results, plans nHCM filing for aficamten in Q4

Nov 4Quarterly updateaficamten Cytokinetics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.